Skip to main content

Xeris Biopharma Holdings, Inc.

XERS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001867096

In the last 90 days, Xeris Biopharma Holdings, Inc. insiders filed 0 open-market purchases and 11 sales; 242 institutions reported holding it in 13F filings for Q2 2026, worth $857.1M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Xeris Biopharma Holdings, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of XERS: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders10394−9
Shares33.2M28.2M−5.04M (−15.2%)
Value$149.7M$114.9M−$34.8M (−23.3%)

New holders (25)

Institutions that held Xeris Biopharma Holdings, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to XERS in Q2 2021
InstitutionSharesValue% of portfolio
SG Americas Securities, LLC244,228$994.0K0.01%
Susquehanna Fundamental Investments, LLC143,639$585.0K0.01%
Nomura Holdings Inc100,000$411.0K0.00%
Raymond James & Associates92,900$378.0K0.00%
HRT Financial LP90,515$368.0K0.00%
Susquehanna International Group, LLP80,732$329.0K0.00%
Dimensional Fund Advisors LP80,187$326.0K0.00%
PEAK6 Investments LLC72,362$295.0K0.01%
Chevy Chase Trust Holdings, Inc.51,243$209.0K0.00%
Cetera Advisor Networks LLC44,740$182.0K0.00%
AE Wealth Management LLC40,970$167.0K0.00%
Great Lakes Advisors, LLC34,841$142.0K0.00%
Squarepoint Ops LLC32,603$133.0K0.00%
Algert Global LLC19,840$81.0K0.03%
Powell Investment Advisors, LLC20,000$81.0K0.05%
Whitener Capital Management, Inc.14,000$56.0K0.02%
Principal Financial Group Inc13,716$56.0K0.00%
Raymond James Financial Services Advisors, Inc.13,027$53.0K0.00%
Simplex Trading, LLC13,229$53.0K0.00%
Virtu Financial LLC11,820$48.0K0.00%
Kore Private Wealth LLC10,120$41.0K0.00%
Benjamin F. Edwards & Company, Inc.3,000$12.0K0.00%
Geneos Wealth Management Inc.1,000$4.00K0.00%
Advisory Services Network, LLC45$00.00%
Lloyd Advisory Services, LLC.71$00.00%

Sold out (34)

Institutions that held Xeris Biopharma Holdings, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.